8-K: Tenax Therapeutics Appoints Thomas A. McGauley as Interim CFO

Tenax Therapeutics has appointed Thomas A. McGauley as Interim Chief Financial Officer, effective December 2, 2024, replacing Lawrence R. Hoffman.

Summary

• Tenax Therapeutics has appointed Thomas A. McGauley as its Interim Chief Financial Officer, effective December 2, 2024.
• Mr. McGauley will take over the accounting and finance functions, serving as the principal financial officer and principal accounting officer.
• He will provide services through Danforth Advisors, LLC, under an existing consulting agreement.
• Danforth will receive $410 per hour for Mr. McGauley's services, with a potential annual increase of up to 4%.
• The consulting agreement can be terminated with cause immediately or without cause with 30 days' notice.
• Lawrence R. Hoffman's consultancy services as Interim CFO have transitioned to Mr. McGauley on the same date.
• Mr. McGauley has over 25 years of financial and executive experience, including roles at CBIZ and Galectin Therapeutics.

Sentiment

Score: 7

Explanation: The document is neutral to slightly positive. The appointment of an experienced interim CFO is a positive step, but the interim nature and reliance on a consulting agreement introduce some uncertainty.

Positives

• The appointment of Thomas A. McGauley brings a seasoned financial executive with over 25 years of experience to the role of Interim CFO.
• Mr. McGauley's experience includes serving as interim CFO for other life science companies, which is directly relevant to Tenax Therapeutics.
• The existing consulting agreement with Danforth Advisors provides a structured and potentially cost-effective way to engage Mr. McGauley's services.
• The hourly rate of $410 is clearly defined, with a potential annual increase of up to 4%, providing cost predictability.

Negatives

• The appointment is on an interim basis, which may suggest a lack of long-term stability in the CFO role.
• The reliance on a consulting agreement means that Mr. McGauley is not a full-time employee, which could impact his level of commitment and availability.

Risks

• The transition of CFO responsibilities could create a temporary disruption in the company's financial operations.
• The reliance on a consulting agreement means that the company could lose Mr. McGauley's services with 30 days' notice without cause.
• The potential annual increase of up to 4% in the hourly rate could lead to increased costs over time.

Future Outlook

The document does not contain any specific forward-looking statements or guidance beyond the appointment of the new interim CFO.

Management Comments

• The Board of Directors appointed Thomas A. McGauley as Interim Chief Financial Officer.
• Mr. McGauley will be responsible for the Company's accounting and finance functions.

Industry Context

The appointment of an interim CFO is not uncommon in the life sciences industry, particularly for companies undergoing transitions or growth phases. The use of consulting firms like Danforth Advisors for interim financial leadership is also a common practice.

Comparison to Industry Standards

• The use of consulting firms for interim CFO roles is a common practice in the life sciences industry, with companies like BioMarin and Vertex often using similar arrangements during transitional periods.
• The hourly rate of $410 is within the typical range for experienced financial consultants in the life sciences sector, although rates can vary based on experience and location.
• The 30-day termination clause is standard in consulting agreements, providing flexibility for both the company and the consultant.

Management Changes

Stakeholder Impact

• Shareholders may view the appointment of an experienced interim CFO as a positive step towards financial stability.
• Employees in the finance department will be working under new leadership.
• The change in CFO is unlikely to have a direct impact on customers or suppliers.

Key Dates

Keywords

Interim CFO, Chief Financial Officer, Tenax Therapeutics, Thomas A. McGauley, Danforth Advisors, Financial Officer, Accounting Officer, Consulting Agreement, Life Sciences, Executive Appointment